P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY

• Uwe Platzbecker,
• Sheida Hayati,
• Aarif Ahsan,
• Amit Verma,
• Srinivas Aluri,
• Shelonitda Rose,
• Anita Gandhi,
• Rajasekhar Nvs Suragani,
• Sadanand Vodala

Affiliations

Uwe Platzbecker

1 Department for Hematology, Cell Hematology and Hemostaseology, Leipzig University Hospital, Leipzig, Germany

Sheida Hayati

2 Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, NJ, United States

Aarif Ahsan

3 Translational Medicine, Bristol Myers Squibb, Summit, NJ, United States

Amit Verma

4 Department of Oncology, Albert Einstein College of Medicine, New York, NY, United States

Srinivas Aluri

4 Department of Oncology, Albert Einstein College of Medicine, New York, NY, United States

Shelonitda Rose

5 Global Drug Development, Bristol Myers Squibb, Summit, NJ, United States

Anita Gandhi

3 Translational Medicine, Bristol Myers Squibb, Summit, NJ, United States

Rajasekhar Nvs Suragani

3 Translational Medicine, Bristol Myers Squibb, Summit, NJ, United States

Sadanand Vodala

3 Translational Medicine, Bristol Myers Squibb, Summit, NJ, United States